OpRegen

BIOLOGICAL2 trials

Sponsors

Hoffmann-La Roche, Genentech, Inc.

Conditions

Age-Related Macular DegenerationGeographic Atrophy

Phase 1

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Active, not recruitingNCT02286089

Hoffmann-La RocheAge-Related Macular Degeneration

Start: 2015-04-01End: 2031-01-31Updated: 2026-07-27

Phase 2

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

RecruitingNCT05626114

Genentech, Inc.Geographic Atrophy

Start: 2023-03-23End: 2031-03-01Target: 60Updated: 2026-09-15

Related Papers

Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval

npj Regenerative Medicine2025-04-194 citations

Survival of Neural Progenitors Derived from Human Embryonic Stem Cells Following Subretinal Transplantation in Rodents

Journal of Ocular Pharmacology and Therapeutics2023-05-043 citations